Profiel
Jacob J.
Clement joined MIGENIX, Inc. in August 2002.
He is Chief Science Officer and Senior Vice President-Science and Technology for MIGENIX.
Previously, he held various executive and senior management positions with Abbott Laboratories, Scriptgen Pharmaceuticals and Essential Therapeutics.
Dr. Clement received a PhD and a MSPH from the University of North Carolina, an MS degree from Roosevelt University and a BA degree from St. Mary's University.
Eerdere bekende functies van Jacob J. Clement
| Bedrijven | Functie | Einde |
|---|---|---|
MIGENIX, Inc.
 MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | Hoofd Techniek/Wetenschap/O&O | 31-01-2009 |
Opleiding van Jacob J. Clement
| The University of North Carolina at Charlotte | Doctorate Degree |
| Roosevelt University | Graduate Degree |
| Saint Mary's University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | Health Technology |
